206 related articles for article (PubMed ID: 26053181)
1. MicroRNA-106b inhibits osteoclastogenesis and osteolysis by targeting RANKL in giant cell tumor of bone.
Wang T; Yin H; Wang J; Li Z; Wei H; Liu Z; Wu Z; Yan W; Liu T; Song D; Yang X; Huang Q; Zhou W; Xiao J
Oncotarget; 2015 Aug; 6(22):18980-96. PubMed ID: 26053181
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-16-5p Inhibits Osteoclastogenesis in Giant Cell Tumor of Bone.
Sang S; Zhang Z; Qin S; Li C; Dong Y
Biomed Res Int; 2017; 2017():3173547. PubMed ID: 28589137
[TBL] [Abstract][Full Text] [Related]
3. MiR-126-5p regulates osteoclast differentiation and bone resorption in giant cell tumor through inhibition of MMP-13.
Wu Z; Yin H; Liu T; Yan W; Li Z; Chen J; Chen H; Wang T; Jiang Z; Zhou W; Xiao J
Biochem Biophys Res Commun; 2014 Jan; 443(3):944-9. PubMed ID: 24360951
[TBL] [Abstract][Full Text] [Related]
4. MiR-30a inhibits osteolysis by targeting RunX2 in giant cell tumor of bone.
Huang Q; Jiang Z; Meng T; Yin H; Wang J; Wan W; Cheng M; Yan W; Liu T; Song D; Chen H; Wu Z; Xu W; Li Z; Zhou W; Xiao J
Biochem Biophys Res Commun; 2014 Oct; 453(1):160-5. PubMed ID: 25264196
[TBL] [Abstract][Full Text] [Related]
5. PTHrP increases RANKL expression by stromal cells from giant cell tumor of bone.
Cowan RW; Singh G; Ghert M
J Orthop Res; 2012 Jun; 30(6):877-84. PubMed ID: 22102368
[TBL] [Abstract][Full Text] [Related]
6. TGF-β induced PAR-1 expression promotes tumor progression and osteoclast differentiation in giant cell tumor of bone.
Wang T; Jiao J; Zhang H; Zhou W; Li Z; Han S; Wang J; Yang X; Huang Q; Wu Z; Yan W; Xiao J
Int J Cancer; 2017 Oct; 141(8):1630-1642. PubMed ID: 28670703
[TBL] [Abstract][Full Text] [Related]
7. CCAAT/enhancer binding protein beta is up-regulated in giant cell tumor of bone and regulates RANKL expression.
Ng PK; Tsui SK; Lau CP; Wong CH; Wong WH; Huang L; Kumta SM
J Cell Biochem; 2010 May; 110(2):438-46. PubMed ID: 20225273
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel inhibits osteoclast formation and bone resorption via influencing mitotic cell cycle arrest and RANKL-induced activation of NF-κB and ERK.
Ang ES; Pavlos NJ; Chim SM; Feng HT; Scaife RM; Steer JH; Zheng MH; Xu J
J Cell Biochem; 2012 Mar; 113(3):946-55. PubMed ID: 22034016
[TBL] [Abstract][Full Text] [Related]
9. MiR-126-5p regulates osteolysis formation and stromal cell proliferation in giant cell tumor through inhibition of PTHrP.
Zhou W; Yin H; Wang T; Liu T; Li Z; Yan W; Song D; Chen H; Chen J; Xu W; Yang X; Wu Z; Xiao J
Bone; 2014 Sep; 66():267-76. PubMed ID: 24973691
[TBL] [Abstract][Full Text] [Related]
10. Sustained autocrine induction and impaired negative feedback of osteoclastogenesis in CD14(+) cells of giant cell tumor of bone.
Avnet S; Salerno M; Zini N; Alberghini M; Gibellini D; Baldini N
Am J Pathol; 2013 Apr; 182(4):1357-66. PubMed ID: 23395086
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue.
Lau YS; Sabokbar A; Gibbons CL; Giele H; Athanasou N
Hum Pathol; 2005 Sep; 36(9):945-54. PubMed ID: 16153456
[TBL] [Abstract][Full Text] [Related]
12. 5-Fluoruracil blocked giant cell tumor progression by suppressing osteoclastogenesis through NF-kappaB signals and blocking angiogenesis.
Song D; Meng T; Xu W; Hou T; Lin Z; Yin H; Li B; Zhou L; Wang T; Han S; Fan T; Miao W; Liu M; Luo J; Zhou W; Li Z; Xiao J
Bone; 2015 Sep; 78():46-54. PubMed ID: 25956534
[TBL] [Abstract][Full Text] [Related]
13. MiR-503 regulates osteoclastogenesis via targeting RANK.
Chen C; Cheng P; Xie H; Zhou HD; Wu XP; Liao EY; Luo XH
J Bone Miner Res; 2014 Feb; 29(2):338-47. PubMed ID: 23821519
[TBL] [Abstract][Full Text] [Related]
14. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.
Yamagishi T; Kawashima H; Ogose A; Ariizumi T; Sasaki T; Hatano H; Hotta T; Endo N
PLoS One; 2016; 11(5):e0154680. PubMed ID: 27163152
[TBL] [Abstract][Full Text] [Related]
15. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors.
Atkins GJ; Haynes DR; Graves SE; Evdokiou A; Hay S; Bouralexis S; Findlay DM
J Bone Miner Res; 2000 Apr; 15(4):640-9. PubMed ID: 10780856
[TBL] [Abstract][Full Text] [Related]
16. Triptolide inhibits osteoclast formation, bone resorption, RANKL-mediated NF-қB activation and titanium particle-induced osteolysis in a mouse model.
Huang J; Zhou L; Wu H; Pavlos N; Chim SM; Liu Q; Zhao J; Xue W; Tan RX; Ye J; Xu J; Ang ES; Feng H; Tickner J; Xu J; Ding Y
Mol Cell Endocrinol; 2015 Jan; 399():346-53. PubMed ID: 25448849
[TBL] [Abstract][Full Text] [Related]
17. Characterization of MicroRNA Expression Profiles in Patients with Giant Cell Tumor.
Qin S; He NB; Yan HL; Dong Y
Orthop Surg; 2016 May; 8(2):212-9. PubMed ID: 27384730
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL.
Ohba T; Cole HA; Cates JM; Slosky DA; Haro H; Ando T; Schwartz HS; Schoenecker JG
J Bone Miner Res; 2014 Jun; 29(6):1431-45. PubMed ID: 24443409
[TBL] [Abstract][Full Text] [Related]
19. Smad3 is the key to transforming growth factor-β1-induced osteoclast differentiation in giant cell tumor of bone.
Lou Z; Yang Y; Ren T; Tang S; Peng X; Lu Q; Sun Y; Guo W
Med Oncol; 2013; 30(3):606. PubMed ID: 23690270
[TBL] [Abstract][Full Text] [Related]
20. Siglec-15, a member of the sialic acid-binding lectin, is a novel regulator for osteoclast differentiation.
Hiruma Y; Hirai T; Tsuda E
Biochem Biophys Res Commun; 2011 Jun; 409(3):424-9. PubMed ID: 21586272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
